Stock comparison
LeMaitre Vascular
Merck &
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
MRK
Merck &
Market cap
$302.33B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | MRK | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 64C | LMAT |
| Benjamin Graham | 89A | 78B | LMAT |
| Philip Fisher | 81C | 63C | LMAT |
| Peter Lynch | 67B | 68B | MRK |
| Joel Greenblatt | 56D | 34F | LMAT |
| Charlie Munger | 68D | 68C | Tie |
| Terry Smith | 69D | 55D | LMAT |
Side-by-side metrics
| Metric | LMAT | MRK |
|---|---|---|
| Market cap | $2.23B | $302.33B |
| P/E (TTM) | 37.1x | 31.5x |
| EV/EBIT | 36.6x | 13.9x |
| ROIC (TTM) | 9.43% | 13.34% |
| Gross margin | 72.39% | 75.91% |
| Net margin | 24.35% | 13.62% |
| Revenue CAGR 5y | 12.75% | 7.45% |
| EPS CAGR 5y | 19.04% | 9.06% |
| Debt / Equity | 0.5x | 1.1x |
| Dividend yield | 0.84% | 2.91% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Debt / Equity0.5xvs 1.1x+56%
- EPS CAGR 5y19.04%vs 9.06%+52%
- Net margin24.35%vs 13.62%+44%
- Revenue CAGR 5y12.75%vs 7.45%+42%
MRK leads on
- Market cap$302.33Bvs $2.23B+99%
- Dividend yield2.91%vs 0.84%+71%
- EV/EBIT13.9xvs 36.6x+62%
- ROIC (TTM)13.34%vs 9.43%+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.